Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for...
Read More Details
Finally We wish PressBee provided you with enough information of ( WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA )
Also on site :
- Is Apple Pay Down? What We Know About the Widespread Outages
- Oscar Winner Stuns On The Red Carpet As The Cannes ‘Godmother’ — What The Prestigious Title Means
- Romanian presidential frontrunner slams ‘authoritarian’ Macron